<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500888</url>
  </required_header>
  <id_info>
    <org_study_id>14-0341</org_study_id>
    <nct_id>NCT02500888</nct_id>
  </id_info>
  <brief_title>Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder</brief_title>
  <official_title>Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate, through a pilot study with about ten cases, if
      bilateral ventral capsulotomy by linear accelerator enable modification of
      obsessive-compulsive symptoms and quality of life in patients with severe and refractory
      obsessive compulsive disorder (OCD) and also investigate possible adverse effects /
      complications of the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About ten patients with severe and refractory OCD will receive bilateral single lesions at
      the bottom of the anterior limb of the internal capsule by linear accelerator. Prior to the
      procedure, a detailed clinical and psychiatric evaluation, plus an extensive battery of
      psychiatric diagnostic tests, severity and progression of OCD, depression / anxiety symptoms,
      presence of tics, psychosocial impairment, quality of life, familial accommodation and
      neuropsychological and personality testes will be performed. Furthermore, the patients will
      be also assessed by serological and neuroimaging tests. The Individuals will be periodically
      evaluated and followed up for one year. The results of the scores of the rating scales will
      be analyzed and compared, as well as the profile of adverse events, cognitive or personality
      changes and improves in clinical tests and neuroimaging studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in OCD symptoms</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of Yale-Brown Obsessive-Compulsive Scale (Y-Bocs) scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life.</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Medical Outcomes Study 36-Item Short-Form Health Survey&quot; (SF-36) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain-derived neurotrophic factor (BDNF) blood dosing</measure>
    <time_frame>12 months</time_frame>
    <description>Serological blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychological tests</measure>
    <time_frame>12 months</time_frame>
    <description>Application of:
Mini Mental Modified (3MS) test
Wechsler of intelligence test
Stroop of colors test
Tracks tests A and B
Boston Naming Test (BNT)
Wechsler Memory Scale Revised (WMS-R)
Wisconsin (WCST) test
Brief Visual Memory Test (BVLT)
Hopkins Verbal Learning Test (HBLT) test
Benton Line Orientation (BLO) test
Grooved Pegboard Test
Finger Tapping test
Complex figure of Rey test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects and complications</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Systematic Assessment for Treatment Emergent Effects&quot; (SAFTEE) Event List and Interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in familial accommodation</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Family Accommodation Scale for Obsessive-Compulsive Disorder&quot; (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety symptoms.</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Beck Anxiety Inventory&quot; (BAI) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms.</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Beck Depression Inventory&quot; (BDI) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in near-infrared spectroscopy (NIRS) brain blood flow</measure>
    <time_frame>12 months</time_frame>
    <description>During application of Stroop psychological test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCD symptoms</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Comprehensive Psychopathological Rating Scale&quot; (CPRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCD symptoms</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;USP-Sensory Phenomena Scale&quot; (USP-SPS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCD symptoms</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Brown Assessment of Beliefs Scale&quot; (BABS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCD symptoms</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;National Institute of Mental Health Global Obsessive-Compulsive Scale&quot; (NIMH OCD Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Functioning</measure>
    <time_frame>Every 3 months until 12 months</time_frame>
    <description>Application of &quot;Global Assessment of Functioning Scale&quot; (GAF)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>OCD</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiosurgery by linear accelerator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery</intervention_name>
    <description>Only one radiation session of about 180 Gy in bilateral internal capsule.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. OCD diagnosis, according to Diagnostic and Statistical Manual of Mental Disorders,
             Fifth Edition (DSM-5) as a major disease entity. If comorbidity with other psychiatric
             or personality disorders, OCD symptoms dominate the clinical picture and precede other
             disorders.

          2. Duration of OCD symptoms of at least five years.

          3. Scores range of the obsessive-compulsive symptoms &quot;Yale-Brown Obsessive-Compulsive
             Scale&quot; (YBOCS) greater than 26 (or greater than 13, if obsessions or compulsions
             alone).

          4. Fill up the criteria for refractory to prior treatments.

          5. Be accepted by the method of &quot;best estimate&quot; for defining the patient is refractory,
             which consisted of confirmation by at least two specialists obsessive-compulsive
             disorder that the patient fulfills the criteria for effective refractory to previous
             treatments.

        Exclusion Criteria:

          1. History of head trauma or post-traumatic amnesia.

          2. Background of systemic or neurological diseases with brain impairment, severe and
             active.

          3. History of current use of substances capable of inducing psychopathological
             manifestations, or signs of cumulative effects of alcohol or drugs in the central
             nervous system (such as cortical atrophy), confirmed by neuroimaging.

          4. pregnancy or lactation.

          5. Refusal to submit to the radiosurgical procedure.

          6. Refusal to accept the informed consent form, or participate.

          7. History of mental retardation and / or inability to understand the informed consent,
             confirmed by neuropsychological tests of the initial evaluation.

          8. Lack of family or companion with proper capacity of understanding of the informed
             consent in patients with comorbid major depression or psychosis that could potentially
             have difficulty performing the appropriate judgment as to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Abreu, M.D.; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulo Abreu, M.D.; Ph.D.</last_name>
    <phone>555133598294</phone>
    <email>paulo.abreu@ufrgs.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcelo Sousa, M.D.; M.Sc</last_name>
    <phone>555199557634</phone>
    <email>mbsousa@hcpa.edu.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Abreu, M.D.; Ph.D.</last_name>
      <phone>555133598294</phone>
      <email>paulo.abreu@ufrgs.br</email>
    </contact>
    <contact_backup>
      <last_name>Marcelo Sousa, M.D.; M.Sc.</last_name>
      <phone>555199557634</phone>
      <email>mbsousa@hcpa.edu.br</email>
    </contact_backup>
    <investigator>
      <last_name>Lucas Lovato, M.D.; M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabiane Caillava, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Oppitz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Ferreira, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcelo Sousa, M.D.; M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Abreu, M.D.; Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl. 1978;(271):5-27.</citation>
    <PMID>277059</PMID>
  </reference>
  <reference>
    <citation>Ballantine HT Jr, Cassidy WL, Flanagan NB, Marino R Jr. Stereotaxic anterior cingulotomy for neuropsychiatric illness and intractable pain. J Neurosurg. 1967 May;26(5):488-95.</citation>
    <PMID>5337782</PMID>
  </reference>
  <reference>
    <citation>Batistuzzo MC, Taub A, Nakano E, D'Alcante CC, de Mathis ME, Hoexter MQ, Miguel EC, Lopes AC. Performance of patients with refractory obsessive-compulsive disorder in the Frontal Systems Behavior Scale. Neurocase. 2009;15(2):157-62. doi: 10.1080/13554790802709047. Epub 2009 Mar 9.</citation>
    <PMID>19274575</PMID>
  </reference>
  <reference>
    <citation>Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7.</citation>
    <PMID>3204199</PMID>
  </reference>
  <reference>
    <citation>BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.</citation>
    <PMID>13688369</PMID>
  </reference>
  <reference>
    <citation>Brandt RA, Salvajoli JV, Oliveira VC, Carmignani M, da Cruz JC, Leal HD, Ferraz L. [Linear accelerator radiosurgery]. Arq Neuropsiquiatr. 1995 Mar;53(1):38-45. Portuguese.</citation>
    <PMID>7575207</PMID>
  </reference>
  <reference>
    <citation>Calvocoressi L, Libman D, Vegso SJ, McDougle CJ, Price LH. Global functioning of inpatients with obsessive-compulsive disorder, schizophrenia, and major depression. Psychiatr Serv. 1998 Mar;49(3):379-81.</citation>
    <PMID>9525801</PMID>
  </reference>
  <reference>
    <citation>Calvocoressi L, Mazure CM, Kasl SV, Skolnick J, Fisk D, Vegso SJ, Van Noppen BL, Price LH. Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior. J Nerv Ment Dis. 1999 Oct;187(10):636-42.</citation>
    <PMID>10535658</PMID>
  </reference>
  <reference>
    <citation>Cecconi JP, Lopes AC, Duran FL, Santos LC, Hoexter MQ, Gentil AF, Canteras MM, Castro CC, Norén G, Greenberg BD, Rauch SL, Busatto GF, Miguel EC. Gamma ventral capsulotomy for treatment of resistant obsessive-compulsive disorder: a structural MRI pilot prospective study. Neurosci Lett. 2008 Dec 12;447(2-3):138-42. doi: 10.1016/j.neulet.2008.09.061. Epub 2008 Sep 27.</citation>
    <PMID>18835422</PMID>
  </reference>
  <reference>
    <citation>Fodstad H, Strandman E, Karlsson B, West KA. Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. Acta Neurochir (Wien). 1982;62(1-2):1-23.</citation>
    <PMID>7048859</PMID>
  </reference>
  <reference>
    <citation>Frighetto L, De Salles A, Wallace R, Ford J, Selch M, Cabatan-Awang C, Solberg T. Linear accelerator thalamotomy. Surg Neurol. 2004 Aug;62(2):106-13; discussion 113-4.</citation>
    <PMID>15261496</PMID>
  </reference>
  <reference>
    <citation>Frighetto L, Bizzi J, Annes RD, Silva Rdos S, Oppitz P. Stereotactic radiosurgery for movement disorders. Surg Neurol Int. 2012;3(Suppl 1):S10-6. doi: 10.4103/2152-7806.91605. Epub 2012 Jan 14.</citation>
    <PMID>22826805</PMID>
  </reference>
  <reference>
    <citation>Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989 Nov;46(11):1012-6.</citation>
    <PMID>2510699</PMID>
  </reference>
  <reference>
    <citation>Lopes AC, Greenberg BD, Canteras MM, Batistuzzo MC, Hoexter MQ, Gentil AF, Pereira CA, Joaquim MA, de Mathis ME, D'Alcante CC, Taub A, de Castro DG, Tokeshi L, Sampaio LA, Leite CC, Shavitt RG, Diniz JB, Busatto G, Norén G, Rasmussen SA, Miguel EC. Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Sep;71(9):1066-76. doi: 10.1001/jamapsychiatry.2014.1193. Retraction in: JAMA Psychiatry. 2015 Dec;72(12):1258.</citation>
    <PMID>25054836</PMID>
  </reference>
  <reference>
    <citation>Guy W, Wilson WH, Brooking B, Manov G, Fjetland O. Reliability and validity of SAFTEE: preliminar analyses. Psychopharmacol Bull. 1986;22(2):397-401.</citation>
    <PMID>3774933</PMID>
  </reference>
  <reference>
    <citation>Hou J, Wu W, Lin Y, Wang J, Zhou D, Guo J, Gu S, He M, Ahmed S, Hu J, Qu W, Li H. Localization of cerebral functional deficits in patients with obsessive-compulsive disorder: a resting-state fMRI study. J Affect Disord. 2012 May;138(3):313-21. doi: 10.1016/j.jad.2012.01.022. Epub 2012 Feb 12.</citation>
    <PMID>22331021</PMID>
  </reference>
  <reference>
    <citation>Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677-736. Review.</citation>
    <PMID>11520916</PMID>
  </reference>
  <reference>
    <citation>Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry. 1994 Mar;55 Suppl:11-7. Review.</citation>
    <PMID>7915709</PMID>
  </reference>
  <reference>
    <citation>Kelly DH, Walter CJ, Sargant W. Modified leucotomy assessed by forearm blood flow and other measurements. Br J Psychiatry. 1966 Sep;112(490):871-81.</citation>
    <PMID>5970906</PMID>
  </reference>
  <reference>
    <citation>KNIGHT G. THE ORBITAL CORTEX AS AN OBJECTIVE IN THE SURGICAL TREATMENT OF MENTAL ILLNESS. THE RESULTS OF 450 CASES OF OPEN OPERATION AND THE DEVELOPMENT OF THE STEREOTACTIC APPROACH. Br J Surg. 1964 Feb;51:114-24.</citation>
    <PMID>14117767</PMID>
  </reference>
  <reference>
    <citation>Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73.</citation>
    <PMID>2768151</PMID>
  </reference>
  <reference>
    <citation>Lévêque M, Carron R, Régis J. Radiosurgery for the treatment of psychiatric disorders: a review. World Neurosurg. 2013 Sep-Oct;80(3-4):S32.e1-9. doi: 10.1016/j.wneu.2013.07.004. Epub 2013 Jul 17. Review.</citation>
    <PMID>23872618</PMID>
  </reference>
  <reference>
    <citation>Lippitz B, Mindus P, Meyerson BA, Kihlström L, Lindquist C. Obsessive compulsive disorder and the right hemisphere: topographic analysis of lesions after anterior capsulotomy performed with thermocoagulation. Acta Neurochir Suppl. 1997;68:61-3.</citation>
    <PMID>9233415</PMID>
  </reference>
  <reference>
    <citation>McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr;51(4):302-8.</citation>
    <PMID>8161290</PMID>
  </reference>
  <reference>
    <citation>Miguel EC, Coffey BJ, Baer L, Savage CR, Rauch SL, Jenike MA. Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette's disorder. J Clin Psychiatry. 1995 Jun;56(6):246-55.</citation>
    <PMID>7775367</PMID>
  </reference>
  <reference>
    <citation>Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J Neuropsychiatry Clin Neurosci. 1994 Fall;6(4):467-77. Review.</citation>
    <PMID>7841817</PMID>
  </reference>
  <reference>
    <citation>Myers JK, Weissman MM, Tischler GL, Holzer CE 3rd, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD Jr, Kramer M, et al. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry. 1984 Oct;41(10):959-67.</citation>
    <PMID>6332591</PMID>
  </reference>
  <reference>
    <citation>Okada K, Ota T, Iida J, Kishimoto N, Kishimoto T. Lower prefrontal activity in adults with obsessive-compulsive disorder as measured by near-infrared spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:7-13. doi: 10.1016/j.pnpbp.2012.11.013. Epub 2012 Dec 5.</citation>
    <PMID>23220093</PMID>
  </reference>
  <reference>
    <citation>Ota T, Iida J, Sawada M, Suehiro Y, Yamamuro K, Matsuura H, Tanaka S, Kishimoto N, Negoro H, Kishimoto T. Reduced prefrontal hemodynamic response in pediatric obsessive-compulsive disorder as measured by near-infrared spectroscopy. Child Psychiatry Hum Dev. 2013 Apr;44(2):265-77. doi: 10.1007/s10578-012-0323-0.</citation>
    <PMID>22833309</PMID>
  </reference>
  <reference>
    <citation>Perse T. Obsessive-compulsive disorder: a treatment review. J Clin Psychiatry. 1988 Feb;49(2):48-55. Review.</citation>
    <PMID>2892831</PMID>
  </reference>
  <reference>
    <citation>Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry. 1997;58 Suppl 13:9-13. Review.</citation>
    <PMID>9402914</PMID>
  </reference>
  <reference>
    <citation>Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984 Oct;41(10):949-58.</citation>
    <PMID>6332590</PMID>
  </reference>
  <reference>
    <citation>Rylander G. [Experiments with gammacapsulotomy in anxiety and compulsive neuroses]. Lakartidningen. 1978 Feb 15;75(7):547-9. Swedish.</citation>
    <PMID>342844</PMID>
  </reference>
  <reference>
    <citation>Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic Apparatus for Operations on the Human Brain. Science. 1947 Oct 10;106(2754):349-50.</citation>
    <PMID>17777432</PMID>
  </reference>
  <reference>
    <citation>Steketee G. Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov;42(9):919-28. Review.</citation>
    <PMID>9429061</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Mathews CA, Li Y, Lin Z, Xiao Z. Brain-derived neurotrophic factor (BDNF) plasma levels in drug-naïve OCD patients are lower than those in healthy people, but are not lower than those in drug-treated OCD patients. J Affect Disord. 2011 Sep;133(1-2):305-10. doi: 10.1016/j.jad.2011.04.002. Epub 2011 May 25.</citation>
    <PMID>21616543</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995 Apr;33(4 Suppl):AS264-79.</citation>
    <PMID>7723455</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

